Literature DB >> 10419458

Competitive inhibition of human immunodeficiency virus type-1 protease by the Gag-Pol transframe protein.

C Paulus1, S Hellebrand, U Tessmer, H Wolf, H G Kräusslich, R Wagner.   

Abstract

The human immunodeficiency virus type-1 (HIV-1) transframe protein p6* is located between the structural and enzymatic domains of the Gag-Pol polyprotein, flanked by the nucleocapsid (NC) and the protease (PR) domain at its amino and carboxyl termini, respectively. Here, we report that recombinant highly purified HIV-1 p6* specifically inhibits mature HIV-1 PR activity. Kinetic analyses and cross-linking experiments revealed a competitive mechanism for PR inhibition by p6*. We further demonstrate that the four carboxyl-terminal residues of p6* are essential but not sufficient for p6*-mediated inhibition of PR activity. Based on these results, we suggest a role of the transframe protein p6* in regulating HIV-1 PR activity during viral replication.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10419458     DOI: 10.1074/jbc.274.31.21539

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  15 in total

1.  Uncoupling human immunodeficiency virus type 1 Gag and Pol reading frames: role of the transframe protein p6* in viral replication.

Authors:  Andreas Leiherer; Christine Ludwig; Ralf Wagner
Journal:  J Virol       Date:  2009-04-29       Impact factor: 5.103

2.  C-Terminal HIV-1 Transframe p6* Tetrapeptide Blocks Enhanced Gag Cleavage Incurred by Leucine Zipper Replacement of a Deleted p6* Domain.

Authors:  Fu-Hsien Yu; Kuo-Jung Huang; Chin-Tien Wang
Journal:  J Virol       Date:  2017-04-28       Impact factor: 5.103

Review 3.  HIV Genome-Wide Protein Associations: a Review of 30 Years of Research.

Authors:  Guangdi Li; Erik De Clercq
Journal:  Microbiol Mol Biol Rev       Date:  2016-06-29       Impact factor: 11.056

4.  Terminal interface conformations modulate dimer stability prior to amino terminal autoprocessing of HIV-1 protease.

Authors:  Johnson Agniswamy; Jane M Sayer; Irene T Weber; John M Louis
Journal:  Biochemistry       Date:  2012-01-24       Impact factor: 3.162

5.  Resistance to nucleoside analog reverse transcriptase inhibitors mediated by human immunodeficiency virus type 1 p6 protein.

Authors:  S Peters; M Muñoz; S Yerly; V Sanchez-Merino; C Lopez-Galindez; L Perrin; B Larder; D Cmarko; S Fakan; P Meylan; A Telenti
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

6.  Proline residues within spacer peptide p1 are important for human immunodeficiency virus type 1 infectivity, protein processing, and genomic RNA dimer stability.

Authors:  Melissa K Hill; Miranda Shehu-Xhilaga; Suzanne M Crowe; Johnson Mak
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

7.  Characterization of a virtually full-length human immunodeficiency virus type 1 genome of a prevalent intersubtype (C/B') recombinant strain in China.

Authors:  L Su; M Graf; Y Zhang; H von Briesen; H Xing; J Köstler; H Melzl; H Wolf; Y Shao; R Wagner
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

8.  Human immunodeficiency virus (HIV) type 1 transframe protein can restore activity to a dimerization-deficient HIV protease variant.

Authors:  Nathalie Dautin; Gouzel Karimova; Daniel Ladant
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

9.  Analysis of natural variants of the human immunodeficiency virus type 1 gag-pol frameshift stem-loop structure.

Authors:  Amalio Telenti; Raquel Martinez; Miguel Munoz; Gabriela Bleiber; Gilbert Greub; Dominique Sanglard; Solange Peters
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

10.  The human immunodeficiency virus type 1 ribosomal frameshifting site is an invariant sequence determinant and an important target for antiviral therapy.

Authors:  Preetha Biswas; Xi Jiang; Annmarie L Pacchia; Joseph P Dougherty; Stuart W Peltz
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.